ESSA Overview

  • Year Founded
  • 2009

Year Founded

  • Status
  • Public

  • Employees
  • 50

Employees

  • Stock Symbol
  • EPIX

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $4.66
  • (As of Tuesday Closing)

ESSA General Information

Description

ESSA Pharma Inc is a pharmaceutical company. The company is focused on the development of small molecule drugs for the treatment of castration-resistant prostate cancer. The company is developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival.

Contact Information

Formerly Known As
ESSA Pharmaceuticals
Ownership Status
Publicly Held
Financing Status
Formerly PE-Backed
Primary Industry
Drug Discovery
Other Industries
Drug Delivery
Stock Exchange
NAS
Corporate Office
  • 999 West Broadway
  • Suite 720
  • Vancouver, British Columbia V5Z 1K5
  • Canada
+1 (778) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

ESSA Stock Performance

(As of Tuesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$4.66 $4.90 $2.58 - $11.67 $207M 44.4M 62.7K -$0.63

ESSA Financials Summary

In Thousands,
USD
TTM 31-Mar-2024 FY 2023 30-Sep-2023 FY 2022 30-Sep-2022 FY 2021 30-Sep-2021
EV 233,837 (16,086) (94,141) 149,930
Revenue 0 0 0 0
EBITDA (30,914) (32,009) (36,816) (36,943)
Net Income (27,734) (26,582) (35,103) (36,805)
Total Assets 137,896 149,122 169,505 198,166
Total Debt 354 80 210 331
Public Fundamental Data provided by Morningstar, Inc. disclaimer

ESSA Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore ESSA‘s full profile, request access.

Request a free trial

ESSA Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
ESSA Pharma Inc is a pharmaceutical company. The company is focused on the development of small molecule drugs for the t
Drug Discovery
Vancouver, Canada
50 As of 2023
00000
000000000 00000

000000

ehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Except
0000 000000000
San Francisco, CA
00 As of 0000
00000 0000-00-00
000000&0

000000

sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labo
0000 00000000
Cambridge, MA
00 As of 0000
00000
00000 0000-00-00
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

ESSA Competitors (32)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Theravance Biopharma Corporation San Francisco, CA 00 000000&0
Merrimack Pharmaceuticals Formerly VC-backed Cambridge, MA 00 00000 00000000 00000
Nektar Therapeutics Formerly VC-backed San Francisco, CA 000 00.000 000000000 00.000
CytomX Therapeutics Formerly VC-backed South San Francisco, CA 000 00000 00000000 00000
Dicerna Pharmaceuticals Formerly VC-backed Lexington, MA 000 00000 000000&0 00000
You’re viewing 5 of 32 competitors. Get the full list »

ESSA Patents

ESSA Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20230373934-A1 Androgen receptor modulators and methods for their use Pending 22-Apr-2022 0000000000
AU-2022340817-A1 Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof Pending 01-Sep-2021 00000000000
CA-3230285-A1 Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof Pending 01-Sep-2021 00000000000
US-20220380378-A1 Androgen receptor modulators and methods for their use Pending 22-Apr-2021 0000000000
CA-3215182-A1 Pharmaceutical compositions comprising inhibitors of the androgen receptor and uses thereof Pending 16-Apr-2021 A61P5/28
To view ESSA’s complete patent history, request access »

ESSA Executive Team (9)

Name Title Board Seat Contact Info
David Parkinson MD President, Chief Executive Officer & Board Member
David Wood Chief Financial Officer
Peter Virsik Chief Operating Officer & Executive Vice President
Alessandra Cesano Ph.D Chief Medical Officer
You’re viewing 4 of 9 executive team members. Get the full list »

ESSA Board Members (13)

Name Representing Role Since
0000 000000 Self Board Member 000 0000
00000 000000000 00 ESSA President, Chief Executive Officer & Board Member 000 0000
00000000 000000 Self Board Member 000 0000
0000 000000 Self Board Member 000 0000
000000 000000000 Self Board Member 000 0000
You’re viewing 5 of 13 board members. Get the full list »

ESSA Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ESSA Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore ESSA‘s full profile, request access.

Request a free trial

ESSA Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Realm Therapeutics 31-Jul-2019 0000000000 000.00 Drug Discovery
To view ESSA’s complete acquisitions history, request access »

ESSA ESG

Risk Overview

Risk Rating

Updated April, 01, 2022

36 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.0

Management

Management is related to actions taken to manage ESG issues

0.000

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 15,638

Rank

00.00

Percentile

Pharmaceuticals

Industry

00 of 1,008

Rank

00.00

Percentile

Biotechnology

Subindustry

00 of 465

Rank

00.00

Percentile

To view ESSA’s complete esg history, request access »

ESSA FAQs

  • When was ESSA founded?

    ESSA was founded in 2009.

  • Who is the founder of ESSA?

    Raymond Andersen Ph.D and Marianne Sadar Ph.D are the founders of ESSA.

  • Who is the CEO of ESSA?

    David Parkinson MD is the CEO of ESSA.

  • Where is ESSA headquartered?

    ESSA is headquartered in Vancouver, Canada.

  • What is the size of ESSA?

    ESSA has 50 total employees.

  • What industry is ESSA in?

    ESSA’s primary industry is Drug Discovery.

  • Is ESSA a private or public company?

    ESSA is a Public company.

  • What is ESSA’s stock symbol?

    The ticker symbol for ESSA is EPIX.

  • What is the current stock price of ESSA?

    As of 18-Jun-2024 the stock price of ESSA is $4.66.

  • What is the current market cap of ESSA?

    The current market capitalization of ESSA is $207M.

  • Who are ESSA’s competitors?

    Theravance Biopharma, Merrimack Pharmaceuticals, Nektar Therapeutics, CytomX Therapeutics, and Dicerna Pharmaceuticals are some of the 32 competitors of ESSA.

  • What is ESSA’s annual earnings per share (EPS)?

    ESSA’s EPS for 12 months was -$0.63.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »